CheckMyRecalls

Boehringer Ingelheim Pharmaceuticals, Inc. recalls Synjardy XR Tablets…

Boehringer Ingelheim Pharmaceuticals, Inc. recalls Synjardy XR Tablets (empagliflozin and metformin hydrochloride exte…

Published
8 Jul 2026
Units affected
560 bottles
Agency
FDA
Country
United States

The hazard

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets), 12.5/1000 mg, 60 Tablets per Bottle, Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA. NDC: 00597-0300-45

Brand / company
Boehringer Ingelheim Pharmaceuticals, Inc.
Codes / lots
Lot 3244413; Exp. 12/31/2028
Distribution
OH
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 8 Jul 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.